Compared to the messenger RNA vaccines from Pfizer Inc./BioNTech SE and Moderna, Inc., Johnson & Johnson’s single-shot Ad26.COV2.S vaccine has fallen out of favor due to safety and manufacturing issues. But it could draw renewed interest with new data showing strong antibody responses among people receiving second shots of the vaccine, along with prior data showing activity against variants of concern.
Eight months after vaccination with the first dose, participants who received a second dose exhibited higher levels of neutralizing antibodies,...






